Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.

These new medicines include Alzheimer's disease treatment Kisunla, ulcerative colitis medication Omvoh, and cancer drug Jaypirca. Of course, Lilly's most important new products are diabetes ...

Self-pay patients with obesity now have additional vial options as well, including at 2.5 mg, 5 mg, 7.5 mg, and 10 mg doses. Lilly is also slashing the price for a month's supply of the two lowest ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...

Eli Lilly (LLY) stock in focus as the company expands Zepbound offerings with new vial formats at discounted prices. Read more here.

Lilly said patients must refill their prescriptions of the two higher-dose vials within 45 days of their first fill to get the same pricing, and would otherwise have to pay as much as $699 for ...

Eli Lilly released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for the ...